PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
178.96%
R&D growth while AGEN reduces spending. John Neff would investigate strategic advantage.
203.49%
G&A growth while AGEN reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
-29.56%
Other expenses reduction while AGEN shows 0.00% growth. Joel Greenblatt would examine efficiency.
185.87%
Operating expenses growth while AGEN reduces costs. John Neff would investigate differences.
185.87%
Total costs growth while AGEN reduces costs. John Neff would investigate differences.
-0.66%
Interest expense reduction while AGEN shows 3.43% growth. Joel Greenblatt would examine advantage.
-29.56%
Both companies reducing D&A. Martin Whitman would check industry patterns.
-185.91%
EBITDA decline while AGEN shows 20.68% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-185.87%
Operating income decline while AGEN shows 21.31% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
15.24%
Other expenses growth while AGEN reduces costs. John Neff would investigate differences.
-92.79%
Pre-tax income decline while AGEN shows 22.58% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-0.66%
Tax expense reduction while AGEN shows 30.37% growth. Joel Greenblatt would examine advantage.
-92.79%
Net income decline while AGEN shows 17.25% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-3998.91%
EPS decline while AGEN shows 23.33% growth. Joel Greenblatt would examine position.
-3998.91%
Diluted EPS decline while AGEN shows 23.33% growth. Joel Greenblatt would examine position.
-95.29%
Share count reduction while AGEN shows 6.89% change. Joel Greenblatt would examine strategy.
-95.29%
Diluted share reduction while AGEN shows 6.89% change. Joel Greenblatt would examine strategy.